Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T cells are novel therapies showing great promise for patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL). Single-arm studies showed significant variations in outcomes across distinct CD19 CAR T-cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Gauthier, Jordan, Gazeau, Nicolas, Hirayama, Alexandre V., Hill, Joshua A., Wu, Vicky, Cearley, Aisling, Perkins, Paula, Kirk, Angela, Shadman, Mazyar, Chow, Victor A., Gopal, Ajay K., Hodges Dwinal, Alexandria, Williamson, Staci, Myers, Jessie, Chen, Andy, Nagle, Sarah, Hayes-Lattin, Brandon, Schachter, Levanto, Maloney, David G., Turtle, Cameron J., Sorror, Mohamed L., Maziarz, Richard T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247364/
https://www.ncbi.nlm.nih.gov/pubmed/35439295
http://dx.doi.org/10.1182/blood.2021014497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247364/
https://www.ncbi.nlm.nih.gov/pubmed/35439295
http://dx.doi.org/10.1182/blood.2021014497

Ejemplares similares